Part of Athagoras
                                                                                                                                                                                                   

In combination products, usability is a regulatory strategy.
For autoinjectors and wearable delivery systems, regulators increasingly treat usability as:

⤷ a risk-control measure
⤷ a labeling determinant
⤷ a post-market obligation

This is explicit in EU MDR Annex I (usability engineering), ISO 62366-1, and combination-product guidance from EU and US authorities.

When devices, drugs, and digital components interact, a weakness in one node can affect the whole system, not just clinically, but also from a regulatory standpoint.

Where does usability sit in your regulatory and lifecycle planning today?

While you focus on innovation, we take care of the regulatory path!